October 9, 2019 | Blog
Deal With It: FTC Regulation of Innovative Biopharmaceuticals Escalates During Record-Breaking M&A Streak
Amid a streak of health care merger and acquisition (M&A) activity in 2018 and 2019, the Federal Trade Commission (FTC) is taking an aggressive stance in its review of biopharmaceutical deals. CBPartners analyses what this means for pharmaceutical M&A.